HK Stock MarketDetailed Quotes

02160 CARDIOFLOW-B

Watchlist
  • 0.800
  • 0.0000.00%
Market Closed Jul 23 16:08 CST
1.93BMarket Cap-3703P/E (TTM)

About CARDIOFLOW-B Company

We are a medical device company focusing on the development and commercialization of innovative transcatheter and surgical solutions in the field of structural heart disease. We are committed to providing doctors and patients with accessible, true, and beautiful medical solutions to treat structural heart disease. Our vision is to build a human-centered, world-leading emerging high-tech medical group. We are deeply involved in a large-scale, rapidly growing structural heart disease medical device market with a seriously inadequate penetration rate, and have a comprehensive structural heart disease product pipeline layout. We attach great importance to R&D and innovation, build a technological innovation system combining industry, education and research, deepen the field of structural heart disease with higher standards and better practices, and are committed to providing high-quality products and services to the global market. Our mission Our mission is to provide accessible, true, and beautiful healthcare solutions for structural heart disease. Our vision Our vision is to build a human-centered, world-leading emerging high-tech medical group. Product pipeline At present, the TAVI series products independently developed by the company have entered more than 500 hospitals in China, and successfully entered nearly 100 overseas hospitals in Argentina, Colombia, Thailand and Russia. The Anchorman left atrial occlusion device product independently developed by the subsidiary Shanghai Zuoxin has been approved by the NMPA for marketing. By introducing innovative therapies into the field of stroke prevention, a strategic pipeline layout in the field of structural heart disease and non-valvular heart disease has been achieved. Furthermore, through independent research and development and joint research and development with global partners, the company has established a comprehensive innovative research and development agency covering TAVI products, left ventricular occlusion products, TMV products, TTV products, and surgical support products. It is committed to building core product competitiveness and providing doctors and patients with true and beautiful medical solutions for the treatment of structural heart disease.

Company Profile

Symbol02160
Company NameCARDIOFLOW-B
ISINKYG6082P1054
Listing DateFeb 4, 2021
Issue Price12.20
Shares Offered205.62M share(s)
FoundedJan 10, 2019
Registered AddressCayman Islands
Chairmanguoming chen
Secretaryxiangmeichenluoer li
Audit InstitutionKPMG
Company CategoryOverseas registration of Mainland Individuals control
Registered OfficeThird Floor, Century Yard, Cricket Square, P.O. Box 902, Grand Cayman, KY1-1103, Cayman Islands
Head Office and Principal Place of BusinessRoom 1901, 19th floor, Lee Garden Phase I, 33 Hysan Avenue, Causeway Bay, Hong Kong
Fiscal Year Ends12-31
Employees592
MarketHong Kong motherboard
Phone(86)(21)38954600
Fax(86)(21)50801305
Emailwcxt@microport.com
Business Minimally Invasive Xintong Medical Technology Co., Ltd. is a medical device company mainly engaged in providing doctors and patients with comprehensive medical solutions to treat structural heart disease. The company's main business is the development and commercialization of transcatheter and surgical solutions in the field of structural heart disease. The company's product line includes transcatheter aortic valve implantation (TAVI) series products, AnchorMan left atrial occlusion products, transcatheter mitral valve (TTV) products, transcatheter tricuspid valve (TTV) products, and surgical support products. The company operates in domestic and foreign markets.

Company Executives

  • Name
  • Position
  • Salary
  • Jeffrey R Lindstrom
  • President, Executive Director, Director and General Manager of Shanghai Minimally Invasive
  • 4.00M
  • guoming chen
  • Presidencies, Non-executive Directors, Chairman of Shanghai Minimally Invasive Heart Connect, Chairman of the Nomination Committee, Remuneration Committee Members, Authorized Representative
  • --
  • liang zhao
  • Executive Director, Senior Vice President
  • 3.91M
  • luying yan
  • Executive Director, Vice President (Regulatory Affairs and Clinical Trials)
  • --
  • junjie zhang
  • Non-executive Directors
  • --
  • xia wu
  • Non-executive Directors
  • --
  • jiahong zhou
  • Independent Non-Executive Director, Chairman of the Audit Committee, Remuneration Committee Members
  • --
  • zhixiang sun
  • Independent Non-Executive Director, Remuneration Committee Chairman, Audit Committee Members, Nomination Committee Members
  • --
  • jiandong ding
  • Independent Non-Executive Director, Audit Committee Members, Nomination Committee Members
  • --
  • yao yao
  • Senior Director of R&D
  • --
  • xiangmei li
  • Joint Company Secretary
  • --
  • nuan ni
  • Senior Director of Finance
  • --
  • luoer chen
  • Joint Company Secretary, Authorized Representative
  • --
  • wei sun
  • Senior Director of Supply Chain
  • --
  • rui qin
  • Group Senior Director of Corporate Development and Project Management
  • --
  • xiaoyan he
  • Senior Director of Group Human Capital and General Management
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
%Chg